Fuso Pharmaceutical Industries,Ltd.

As of March 31, 2026, Fuso Pharmaceutical Industries,Ltd. carries a market capitalization of 20.17B, placing it among publicly traded companies globally. Its enterprise value stands at 43.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fuso Pharmaceutical Industries,Ltd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, Fuso Pharmaceutical Industries,Ltd. has 8.54M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Fuso Pharmaceutical Industries,Ltd. maintains a current ratio of 1.11, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Fuso Pharmaceutical Industries,Ltd.'s stock has declined approximately 4.83% over the past 52 weeks. The 50-day moving average sits at 2,221.54, while the 200-day moving average is 2,241.37.

As of March 31, 2026, Fuso Pharmaceutical Industries,Ltd. holds 4.85B in cash and equivalents against 28.46B in total debt, resulting in a net debt position of 23.62B. Total book value stands at 35.06B, with working capital of 5.65B providing operational flexibility.

Fuso Pharmaceutical Industries,Ltd.'s most recent stock split took place on September 28, 2016 with a 10:1 split ratio.